Edgewise Therapeutics, Inc.
HealthcareNASDAQ:EWTX · NASDAQ Global Select
+$0.90 today
Vol 0.88M · Avg 1.18M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-32.1%
avg -2.9%
ROIC
-36.4%
avg -28.3%
ROA
-30.4%
avg -24.6%
Analysis
ROA is currently the strongest return metric at -30.4% versus its period average of -24.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kevin Koch | President, Chief Executive Officer & Director | $1.15M | — | 66 | $30,615.00 | 0.03% |
Behrad Derakhshan | Chief Operating Officer | $803,100.00 | — | 46 | $180,000.00 | 0.17% |
Joanne Donovan | Chief Medical Officer | $788,323.00 | — | 69 | $75,000.00 | 0.07% |
Alan J. Russell | Co-Founder, Chief Scientific Officer & Director | $737,866.00 | — | 56 | $1.15M | 1.07% |
Michael Nofi | Chief Financial Officer | $97,700.00 | — | 55 | $262,500.00 | 0.24% |
Peter A. Thompson FACP | Co-Founder & Independent Chairman | $80,000.00 | — | 66 | $30,000.00 | 0.03% |
Badreddin Edris | Co-Founder & Independent Director | $55,000.00 | — | 39 | $0.00 | <0.01% |
Robert Blaustein | Chief Development Officer | — | — | 65 | $105,000.00 | 0.10% |
John R. Moore | General Counsel | — | — | 62 | $161,250.00 | 0.15% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$199,403.06
Sells
19
$11.43M
Net Sentiment
$11.23M
Net selling
Most Active
Donovan Joanne M.
7 transactions
1–10 of 20
Analysis
Insiders reported 1 buys worth $199,403.06 and 19 sells worth $11.43M over the last 12 months. That adds up to net selling of $11.23M. Donovan Joanne M. was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.47B
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$1.96B
Galapagos N.V.
GLPG
$1.84B
Mesoblast Limited
NASDAQ:MESO
$1.79B
uniQure N.V.
NASDAQ:QURE
$1.74B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
Who manages EWTX?
Edgewise Therapeutics, Inc. (EWTX) lists 9 active executives. The top listed executive is Alan J. Russell, Co-Founder, Chief Scientific Officer & Director.
Are EWTX insiders buying or selling?
Recent insider activity shows net buying of $50.85M.
Explore More
Continue the stock analysis
Jump to another research area for this company.